Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers [RNA-seq]
RNA-seq (gene expression) · human · 18 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 18 samples: 6 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE285592_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1204943 and SRA study SRP554725. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 18 samples.
How we read this: 6 replicated groups read from 18 sample titles; they account for 18 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8705403 OCI-Ly1_DMSO_Rep1 OCI-Ly1_DMSO
- GSM8705404 OCI-Ly1_DMSO_Rep2 OCI-Ly1_DMSO
- GSM8705405 OCI-Ly1_DMSO_Rep3 OCI-Ly1_DMSO
- GSM8705406 OCI-Ly1_JIB04_150nM_Rep1 OCI-Ly1_JIB04_150nM
- GSM8705407 OCI-Ly1_JIB04_150nM_Rep2 OCI-Ly1_JIB04_150nM
- GSM8705408 OCI-Ly1_JIB04_150nM_Rep3 OCI-Ly1_JIB04_150nM
- GSM8705409 OCI-Ly1_JIB04_500nM_Rep1 OCI-Ly1_JIB04_500nM
- GSM8705410 OCI-Ly1_JIB04_500nM_Rep2 OCI-Ly1_JIB04_500nM
- GSM8705411 OCI-Ly1_JIB04_500nM_Rep3 OCI-Ly1_JIB04_500nM
- GSM8705412 TMD8_DMSO_Rep1 TMD8_DMSO
- GSM8705413 TMD8_DMSO_Rep2 TMD8_DMSO
- GSM8705414 TMD8_DMSO_Rep3 TMD8_DMSO
- GSM8705415 TMD8_JIB04_150nM_Rep1 TMD8_JIB04_150nM
- GSM8705416 TMD8_JIB04_150nM_Rep2 TMD8_JIB04_150nM
- GSM8705417 TMD8_JIB04_150nM_Rep3 TMD8_JIB04_150nM
- GSM8705418 TMD8_JIB04_500nM_Rep1 TMD8_JIB04_500nM
- GSM8705419 TMD8_JIB04_500nM_Rep2 TMD8_JIB04_500nM
- GSM8705420 TMD8_JIB04_500nM_Rep3 TMD8_JIB04_500nM
- GSE293843 Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumors [RNA-Seq] 10 samples shares vulnerability, therapeutic, rna-seq
- GSE309595 Longitudinal Analysis of Multiple Myeloma: Therapeutic Response and Immune Microenvironment Dynamics in the Context of Tumor Heterogeneity [scRNA-seq] 270 samples shares therapeutic, rna-seq
- GSE294016 A macrophage-predominant, immunosuppressive immune microenvironment and subtype-specific therapeutic vulnerabilities in advanced salivary gland cancer [bulk RNA-seq] 95 samples shares therapeutic, rna-seq
- GSE295392 PIKfyve-regulated lipid metabolism as a therapeutic vulnerability in neuroendocrine prostate cancer 82 samples shares vulnerability, therapeutic
- GSE293952 Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma [bulk RNA-seq] 61 samples shares therapeutic, rna-seq
- GSE335924 RNA-seq Identifies FOS as a Potential Therapeutic Target Activating Neural Stem Cells via miR-21/SOX2 Pathway in Hypertensive Intracerebral Hemorrhage 53 samples shares therapeutic, rna-seq
- GSE275637 ATF4-Mediated Metabolic Stress Response as a Therapeutic Vulnerability in Chordoma 50 samples shares vulnerability, therapeutic
- GSE290805 Meningioma microenvironment harbors a rich immune landscape with therapeutic implications (Bulk RNA-seq part) 47 samples shares therapeutic, rna-seq
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.